This article is part of the network’s archive of useful research information. This article is closed to new comments due to inactivity. We welcome new content which can be done by submitting an article for review or take part in discussions in an open topic or submit a blog post to take your discussions online.
In consultation with colleagues at WHO, we are reviewing the following research tools:
- Clinical Characterization Protocol
- Severe Acute Respiratory Infection Data Tools
- Viral Haemorrhagic Fever Data Tools
- Ebola Data Tools
If you want to use these research tools or if you require further information, please contact the ISARIC team.
Also By
ISARIC
- Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19
- What is the recovery rate and risk of long-term consequences following a diagnosis of COVID-19? - A harmonised, global longitudinal observational study
- An open-label, randomized, non-inferiority trial of the efficacy and safety of ciprofloxacin versus streptomycin + ciprofloxacin in the treatment of bubonic plague (IMASOY): study protocol for a rando